261 related articles for article (PubMed ID: 34952480)
1. Chemotherapy after immune checkpoint inhibitor failure in metastatic melanoma: a retrospective multicentre analysis.
Goldinger SM; Buder-Bakhaya K; Lo SN; Forschner A; McKean M; Zimmer L; Khoo C; Dummer R; Eroglu Z; Buchbinder EI; Ascierto PA; Gutzmer R; Rozeman EA; Hoeller C; Johnson DB; Gesierich A; Kölblinger P; Bennannoune N; Cohen JV; Kähler KC; Wilson MA; Cebon J; Atkinson V; Smith JL; Michielin O; Long GV; Hassel JC; Weide B; Haydu LE; Schadendorf D; McArthur G; Ott PA; Blank C; Robert C; Sullivan R; Hauschild A; Carlino MS; Garbe C; Davies MA; Menzies AM
Eur J Cancer; 2022 Feb; 162():22-33. PubMed ID: 34952480
[TBL] [Abstract][Full Text] [Related]
2. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition.
Knispel S; Gassenmaier M; Menzies AM; Loquai C; Johnson DB; Franklin C; Gutzmer R; Hassel JC; Weishaupt C; Eigentler T; Schilling B; Schummer P; Sirokay J; Kiecker F; Owen CN; Fleischer MI; Cann C; Kähler KC; Mohr P; Bluhm L; Niebel D; Thoms KM; Goldinger SM; Reinhardt L; Meier F; Berking C; Reinhard R; Susok L; Ascierto PA; Drexler K; Pföhler C; Tietze J; Heinzerling L; Livingstone E; Ugurel S; Long GV; Stang A; Schadendorf D; Zimmer L
Eur J Cancer; 2021 May; 148():61-75. PubMed ID: 33735811
[TBL] [Abstract][Full Text] [Related]
3. MAPKinase inhibition after failure of immune checkpoint blockade in patients with advanced melanoma - An evaluation of the multicenter prospective skin cancer registry ADOREG.
Kreft S; Glutsch V; Zaremba A; Schummer P; Mohr P; Grimmelmann I; Gutzmer R; Meier F; Pföhler C; Sachse MM; Meiss F; Forschner A; Haferkamp S; Welzel J; Terheyden P; Herbst R; Utikal J; Kaatz M; Weishaupt C; Kreuter A; Debus D; Duecker P; Sindrilaru A; Löffler H; Schley G; Weichenthal M; Schadendorf D; Ugurel S; Gesierich A; Schilling B
Eur J Cancer; 2022 May; 167():32-41. PubMed ID: 35366571
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer.
Cabezas-Camarero S; Cabrera-Martín MN; Merino-Menéndez S; Paz-Cabezas M; García-Barberán V; Sáiz-Pardo Sanz M; Iglesias-Moreno M; Alonso-Ovies A; Pérez-Segura P
Oncologist; 2021 Jun; 26(6):e1018-e1035. PubMed ID: 33751752
[TBL] [Abstract][Full Text] [Related]
5. Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?
Klee G; Hagelstein V; Kurzhals JK; Zillikens D; Terheyden P; Langan EA
Melanoma Res; 2022 Oct; 32(5):360-365. PubMed ID: 35855658
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy following immune checkpoint inhibitors in patients with locally advanced or metastatic urothelial carcinoma.
Meynard L; Dinart D; Delaunay B; Fléchon A; Saldana C; Lefort F; Gravis G; Thiery-Vuillemin A; Cancel M; Coquan E; Ladoire S; Maillet D; Rolland F; Boughalem E; Martin S; Laramas M; Crouzet L; Abbar B; Falkowski S; Pouessel D; Roubaud G
Eur J Cancer; 2022 Nov; 175():43-53. PubMed ID: 36088671
[TBL] [Abstract][Full Text] [Related]
7. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine.
Lee CK; Jung M; Choi HJ; Kim HR; Kim HS; Roh MR; Ahn JB; Chung HC; Heo SJ; Rha SY; Shin SJ
Cancer Res Treat; 2015 Oct; 47(4):781-9. PubMed ID: 25687848
[TBL] [Abstract][Full Text] [Related]
8. Immune checkpoint inhibitors in advanced or metastatic mucosal melanoma: a systematic review.
Li J; Kan H; Zhao L; Sun Z; Bai C
Ther Adv Med Oncol; 2020; 12():1758835920922028. PubMed ID: 32489431
[TBL] [Abstract][Full Text] [Related]
9. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
10. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
[TBL] [Abstract][Full Text] [Related]
11. Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
Bouchereau S; Chaplain L; Fort M; Beauchet A; Sidibé T; Chapalain M; Gonzalez-Lara L; Longvert C; Blom A; Saiag P; Funck-Brentano E
Br J Cancer; 2021 Sep; 125(7):948-954. PubMed ID: 34262147
[TBL] [Abstract][Full Text] [Related]
12. Real-world efficacy of anti-PD-1 antibody or combined anti-PD-1 plus anti-CTLA-4 antibodies, with or without radiotherapy, in advanced mucosal melanoma patients: A retrospective, multicenter study.
Umeda Y; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Onuma T; Kuwatsuka Y; Fujimoto N; Kaneko T; Onishi M; Namikawa K; Yamazaki N; Nakamura Y
Eur J Cancer; 2021 Nov; 157():361-372. PubMed ID: 34563991
[TBL] [Abstract][Full Text] [Related]
13. Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients.
Vera Aguilera J; Paludo J; McWilliams RR; Zhang H; Li Y; Kumar AB; Failing J; Kottschade LA; Block MS; Markovic SN; Dong H; Dronca RS; Yan Y
Melanoma Res; 2020 Aug; 30(4):364-375. PubMed ID: 32404734
[TBL] [Abstract][Full Text] [Related]
14. Real-world efficacy and toxicity of combined nivolumab and ipilimumab in patients with metastatic melanoma.
Parakh S; Randhawa M; Nguyen B; Warburton L; Hussain MA; Cebon J; Millward M; Yip D; Ali S
Asia Pac J Clin Oncol; 2019 Feb; 15(1):26-30. PubMed ID: 30426665
[TBL] [Abstract][Full Text] [Related]
15. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma.
Klemen ND; Wang M; Feingold PL; Cooper K; Pavri SN; Han D; Detterbeck FC; Boffa DJ; Khan SA; Olino K; Clune J; Ariyan S; Salem RR; Weiss SA; Kluger HM; Sznol M; Cha C
J Immunother Cancer; 2019 Jul; 7(1):196. PubMed ID: 31340861
[TBL] [Abstract][Full Text] [Related]
16. Real-life data for first-line combination immune-checkpoint inhibition and targeted therapy in patients with melanoma brain metastases.
Hilbers ML; Dimitriou F; Lau P; Bhave P; McArthur GA; Zimmer L; Kudura K; Gérard CL; Levesque MP; Michielin O; Dummer R; Cheng PF; Mangana J
Eur J Cancer; 2021 Oct; 156():149-163. PubMed ID: 34454317
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of anti-PD-1 inhibitor combined with nab-paclitaxel in Chinese patients with refractory melanoma.
Li JJ; Wang JH; Dingv Y; Li DD; Wen XZ; Zhao JJ; Jiang H; Liu X; Huang FX; Zhang XS
J Cancer Res Clin Oncol; 2022 May; 148(5):1159-1169. PubMed ID: 34181096
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of immune checkpoint inhibitors for in-transit melanoma.
Nan Tie E; Lai-Kwon J; Rtshiladze MA; Na L; Bozzi J; Read T; Atkinson V; Au-Yeung G; Long GV; McArthur GA; Sandhu S; Saw R; Walpole E; Menzies A; Smithers M; Gyorki DE
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32376722
[TBL] [Abstract][Full Text] [Related]
19. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis.
Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R
Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134
[TBL] [Abstract][Full Text] [Related]
20. Real-world efficacy and safety of axitinib in combination with anti-programmed cell death-1 antibody for advanced mucosal melanoma.
Tang B; Mo J; Yan X; Duan R; Chi Z; Cui C; Si L; Kong Y; Mao L; Li S; Zhou L; Lian B; Wang X; Bai X; Xu H; Li C; Dai J; Guo J; Sheng X
Eur J Cancer; 2021 Oct; 156():83-92. PubMed ID: 34425407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
